Continuing to raise the bar in CLL<\/b><\/p>\n
\nAt ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne\u2019s strategy to lead in hematology science and patient impact by setting the standard today \u2013 while helping to shape the future of CLL.<\/p>\n
Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:<\/b><\/p>\n
\n\u201cSeventy-eight-month follow-up data from SEQUOIA underscore what it truly takes to lead in CLL over the long term: long-term efficacy, ability for sequencing treatments, and confidence in first-line treatment decisions. Building on that leadership, we\u2019re excited to be rapidly advancing the next generation of medicines, including sonrotoclax-based combinations and our BTK degrader BGB-16673, which are designed to extend what is possible for patients across lines of therapy.\u201d<\/p>\n
Key data presentations in CLL include:<\/b><\/p>\n Accelerating a high-potential solid tumor portfolio<\/strong><\/p>\n \nBeOne is highlighting strong momentum across its deep and diverse solid tumor portfolio at ASCO, with seven unique assets featured in three oral presentations and eight posters. These data span both in-line and pipeline therapies, including results demonstrating the differentiated profile of PD-1 inhibitor TEVIMBRA\u00ae<\/sup> (tislelizumab) across lung and gastrointestinal cancers, as well as in combination with the novel HER2-targeting agent ZIIHERA\u00ae<\/sup> (zanidatamab). The Company\u2019s development superhighway is accelerating progress across all stages of development, generating compelling clinical data that support the potential of these therapies to reshape treatment in areas of high unmet need.<\/p>\n Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said:<\/strong><\/p>\n \n\u201cAt ASCO 2026, we are demonstrating the strength of BeOne\u2019s science, the scale of our pipeline, and the speed at which we are delivering innovation for patients. With multiple programs moving simultaneously toward pivotal trials, we are building durable disease leadership across breast, gynecologic, lung and gastrointestinal cancers \u2013 areas where substantial unmet patient need remains.\u201d<\/p>\n \nKey data presentations across our solid tumor programs include:<\/p>\n Investor webcast to highlight pipeline data at ASCO<\/b><\/p>\n \nBeOne will host an investor webcast on June 1, 2026, at 7:00 PM CDT\/8:00 PM EDT, led by John V. Oyler, Co-Founder, Chairman, and CEO, alongside the Company\u2019s leadership team and invited key opinion leaders. The webcast will review clinical and corporate highlights from ASCO, provide updates on BeOne\u2019s global R&D pipeline and platforms, and discuss the strategic priorities and execution capabilities driving the Company\u2019s long-term growth.<\/p>\n \nWebcast access details are available in the Investors section of BeOne\u2019s website at http:\/\/ir.beonemedicines.com<\/a>, https:\/\/hkexir.beonemedicines.com<\/a>, and https:\/\/sseir.beonemedicines.com<\/a>. An archived webcast will be available on the Company\u2019s website.<\/p>\n Full list of BeOne\u2019s presentations at ASCO:<\/i><\/b><\/p>\n Hematology<\/i><\/b><\/p>\n BRUKINSA\u00ae<\/sup> (Zanubrutinib)<\/b><\/p>\n Abstract Title<\/b><\/p>\n<\/td>\n Presentation Details<\/b><\/p>\n<\/td>\n Lead Author<\/b><\/p>\n<\/td>\n<\/tr>\n \nSubsequent therapies and time to second progression-free survival events in treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab in SEQUOIA<\/p>\n<\/td>\n Poster Presentation:<\/b> 544<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nConstantine S. Tam<\/p>\n<\/td>\n<\/tr>\n \nNavigating the post\u2013covalent Bruton tyrosine kinase inhibitor landscape in mantle cell lymphoma: Real-world insights on treatment patterns, discontinuation, and healthcare resource utilization<\/p>\n \n\u00a0<\/p>\n<\/td>\n Poster Presentation:<\/b> 556<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nAlvaro Alencar<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReal-world outcomes among Medicare beneficiaries treated with first-line Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia<\/p>\n<\/td>\n Poster Presentation:<\/b> 545<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nDaniel A. Ermann<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReal-world impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization in patients with chronic lymphocytic leukemia<\/p>\n<\/td>\n Poster Presentation:<\/b> 540<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nMichael Fradley<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nReal-world treatment survival outcomes for zanubrutinib and acalabrutinib monotherapy among treatment-na\u00efve patients with chronic lymphocytic leukemia in the United States<\/p>\n<\/td>\n Poster Presentation:<\/b> 543<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nRyan Jacobs<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nA real-world comparison of treatment and survival outcomes with zanubrutinib and acalabrutinib monotherapy among patients with relapsed or refractory mantle cell lymphoma in the United States<\/p>\n<\/td>\n Poster Presentation:<\/b> 560<\/p>\n \n\u00a0<\/p>\n Session Title:<\/b> Poster Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n \n\u00a0<\/p>\n Session Date\/Time: <\/b>June 1, 2026, 9:00 AM-12:00 PM CDT<\/p>\n<\/td>\n \nYucai Wang<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nIncidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib<\/p>\n<\/td>\n Abstract Number:<\/b> e19020<\/p>\n<\/td>\n \nRyan Jacobs<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nRisk factors for second primary malignancies in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma: A real-world study<\/p>\n<\/td>\n Abstract Number:<\/b> e19022<\/p>\n<\/td>\n \nLili Zhou<\/p>\n<\/td>\n<\/tr>\n \nCharacterizing patient self-reported adherence to BTKis and symptoms in CLL\/SLL using an electronic patient-reported outcomes platform<\/p>\n<\/td>\n Abstract Number:<\/b> e19030<\/p>\n<\/td>\n \nMustafa Ascha<\/p>\n<\/td>\n<\/tr>\n \nReal-world treatment utilization, sequencing patterns, and healthcare resource utilization in Waldenstr\u00f6m macroglobulinemia<\/p>\n<\/td>\n Abstract Number:<\/b> e19056<\/p>\n<\/td>\n \nJorge Castillo<\/p>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Sonrotoclax<\/b><\/p>\n\n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260521195975\/en\/2494825\/3\/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg\"){kind=logo}
<\/td>\n<\/tr>\n